Clinical Trials

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Julien, M.
Right arrow Articles by Hanley, J. A
PubMed
Right arrow PubMed Citation
Right arrow Articles by Julien, M.
Right arrow Articles by Hanley, J. A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Clinical Trials, Vol. 5, No. 2, 107-115 (2008)
DOI: 10.1177/1740774508089511
© 2008 The Society for Clinical Trials

Profile-specific survival estimates: Making reports of clinical trials more patient-relevant

Marilyse Julien

Department of Mathematics and Statistics, McGill University Montreal, Quebec, Canada

James A Hanley

Department of Epidemiology, Biostatistics and Occupational Health, McGill University Montreal, Quebec, Canada, james.hanley{at}mcgill.ca

Background When considering treatment options, a physician needs to know the prognosis corresponding to the risk profile of the patient seeking treatment. Reports of clinical trials generally address treatment-specific survival probabilities only in the aggregate, i.e., for the typical patient, and often express the difference in survival as a hazard ratio. Such summaries do not provide treatment-specific survival probabilities (and thus the absolute difference in these probabilities) for patient profiles that are not near the typical of those in the trial. Despite the fact that Cox intended his hazard regression method to be used to produce such profile-specific survival estimates, and even showed how to calculate them, authors are either unaware that this is possible, or else choose not to report them.

Purpose To illustrate how treatment- and profile-specific survival estimates are obtained from the Cox method, and can be displayed in a compact form.

Methods We derive treatment- and profile-specific survival probabilities from the estimated survival function for the `reference' profile. Data from the Systolic Hypertension in the Elderly Program study serve as an illustration.

Results Two different formats, tabular and nomogram-based, allow the entire set of estimated treatment- and profile-specific survival probabilities to be reported.

Limitations Estimates are limited to the profiles within the covariate-space spanned by the trial, and depend on the correctness of the model.

Conclusion Treatment- and profile-specific survival estimates are practice-relevant, almost never reported, estimable from the Cox model, and easy to report in a compact form. Clinical Trials 2008; 5: 107—115. http://ctj.sagepub.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?